Panelists discuss how diagnosis and staging of anal cancer involves digital rectal examination, high-resolution anoscopy with biopsy, p16 testing, and pelvic MRI for accurate staging, while ...

A study led by clinician-scientists and researchers at the National Cancer Centre Singapore (NCCS) has found that the tumor immune microenvironment (TIME) plays a critical role in the progression of ...

On Jan. 24, the FDA issued a warning about the enzyme deficiency in which it urged health care providers to “inform patients prior to treatment” about the risks of taking 5-FU and capecitabine. On ...

You have tucatinib, trastuzumab and capecitabine as cycles of treatment. This means you have the drugs and then a rest to allow your body to recover. Each cycle of treatment lasts 21 days (3 weeks).

Capecitabine (Xeloda®), an oral medication, has been demonstrated to have equal effect as its intravenous counterpart 5-FU in treating colon, [25,26] as well as gastroesophageal, cancers.

Around 300,000 people are treated with 5-FU or capecitabine in the United States each year, but its toxicity could well have prevented FDA approval were it up for approval today. Short of withdrawing ...

Landmark study uncovers role of tumour microenvironment in nasopharyngeal carcinoma progression which supports personalised treatment Molecular ...

The PD-L1 Inhibitors drugs uptake section examines the rate at which newly launched or upcoming potential drugs are being ...

They randomly assigned 748 patients (median age, 59 years; range, 24-75; 69.7% men) to receive capecitabine and oxaliplatin plus either 12 mg daily anlotinib (days 1-14) or 7.5 mg/kg IV ...

In part 1 of LEAP-015 (Lead-in Phase), an initial cohort received induction with lenvatinib 8 mg orally once daily plus pembrolizumab 400 mg intravenously once every 6 weeks (×2) and investigator’s ...